Press Releases Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 17/04/2026 BST			5-day change	1st Jan Change
7.270 ^USD	+1.54%		+0.69%	-17.57%

04-13	Geron Corporation Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary	CI
04-09	Vanda Asks FDA to Withdraw Proposal Extending Drug Review Timelines	MT

Press Releases

04-09	Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines	PR
04-08	Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists	PR
03-19	Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods	PR
03-03	Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years	PR
02-26	Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference	PR
02-25	Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis	PR
02-20	Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation	PR
02-11	Vanda: Q4 Earnings Snapshot	AQ
02-11	Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results	PR
02-04	Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026	PR
01-08	Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder	PR
12-30	Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness	PR
12-11	Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference	PR
12-04	Vanda Pharmaceuticals : FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness	PU
12-04	FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness	PR
11-28	Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness	PR
11-17	Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting	PR
11-05	Vanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference	PR
29/10/25	Vanda: Q3 Earnings Snapshot	AQ
29/10/25	Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results	PR
22/10/25	Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025	PR
08/10/25	Monumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena	PR
01/10/25	Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration	PR
25/09/25	Vanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial"	PR
28/08/25	Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences	PR